The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment

Calvo-Lerma, Joaquim; Hulst, Jessie M.; Boon, Mieke; Martins, Tiago Freire; Ruperto, Mar; Colombo, Carla; Fornés-Ferrer, Victoria; Woodcock, Sandra; Claes, I.; Asseiceira, I.; Garriga, M.; Bulfamante, Anna; Masip, Etna; Walet, Sylvia; Crespo, P.; Valmarana, L.; Martínez-Barona, Sandra; Pereira, Luí­sa Álvares; Boeck, K. De; Ribes-Koninckx, Carmen

doi:10.1016/j.jand.2019.01.003

Cited by 27 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Australian adolescents aged 12-18 years also showed a decline of PUFA and n-3 FA intake from 1995 to 2012 [19]. In line with these results, recent reports described that adolescents from developed countries did not meet the recommendations for PUFA or n-3 FA intake [12,33,34]. A previous study of Korean adults showed that PUFA intake increased steadily but was more prominent in n-6 FA intake than in n-3 FA intake [22].…”

Section: Discussionsupporting

confidence: 67%

Trends in Dietary Intake of Total Fat and Fatty Acids Among Korean Adolescents from 2007 to 2017

Song

Shim

2019

Nutrients

View full text Add to dashboard Cite

We analyzed the trends in dietary intake of total fat and fatty acids among Korean adolescents during 2007–2017. A total of 6406 adolescents from the 2007–2017 Korea National Health and Examination Surveys were selected. Total fat and fatty acids intakes were calculated based on single 24-hour recall data and presented as grams (g) and percentage of energy intake (% kcal) across the survey period. Linear trends in intake across the survey period were compared using the multiple regression model. Total fat intake increased during the 11-year period from 54.3 g (21.7% kcal) to 61.8 g (25.2% kcal). Saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) intakes changed from 17.8 g (7.1% kcal) and 17.2 g (6.8% kcal) to 20.6 g (8.4% kcal) and 20.7 g (8.4% kcal) over time, respectively. For polyunsaturated fatty acids (PUFA), n-3 fatty acid intake did not change during the survey period. The proportions of individuals who had total fat and SFA above the recommendations increased across the survey period: 13.7% to 27.5% for total fat and 36.0% to 49.7% for SFA. Among Korean adolescents, dietary fat intake increased over time and the increases in SFA and MUFA intake were prominent. Monitoring dietary fat intake is helpful to suggest dietary guidelines and health policies.

show abstract

Section: Discussionsupporting

confidence: 67%

Trends in Dietary Intake of Total Fat and Fatty Acids Among Korean Adolescents from 2007 to 2017

Song

Shim

2019

Nutrients

View full text Add to dashboard Cite

show abstract

“…Food lipids are important in diets of infants and children, especially when digestive disorders occur such as exocrine pancreatic insufficiency (EPI), as they supply metabolic energy and phospholipids, the main constituents of biological membranes (Briefel, Reidy, Karwe, & Devaney, 2004). Among lipidcontaining foods, dairy products are highly consumed by childhood population (Calvo-Lerma et al, 2019). Cheese is particularly rich in lipid and a good source of essential nutrients such as protein, bioactive peptides, vitamins and minerals (Walther, Schmid, Sieber, & Wehrmüller, 2008).…”

Section: Introductionmentioning

confidence: 99%

In vitro study of cheese digestion: Effect of type of cheese and intestinal conditions on macronutrients digestibility

Asensio-Grau

Peinado

Heredia

et al. 2019

LWT

View full text Add to dashboard Cite

Exocrine Pancreatic Insufficiency (EPI) implies maldigestion, being pancreatic enzyme replacement therapy the treatment to enhance digestibility. This study aims at analysing the influence of cheese-related factors and intestinal conditions on macronutrients digestibility. Fresh-cow, fresh-goat, mild and aged cheeses were in vitro digested under different intestinal conditions of pH (6 or 7), bile concentration (1 or 10mmol/L) and pancreatic enzymes (0-4000 LU/g fat) in order to in vitro mimic the intestinal conditions of a healthy adult and of an individual suffering of EPI. Under intestinal conditions of EPI (pH 6, bile 1mmol/L), lipids of fresh-goat and aged cheeses were more easily digested than those of fresh-cow and mild cheeses. In fact, 2000 LU/g fat of enzymatic dosage was enough to achieve a lipolysis extent of 80 and 100% 100 % in aged and fresh-goat cheeses, respectively. In contrast, proteolysis was higher in freshcow cheese and ripened (mild or aged) than in fresh-goat one regardless the intestinal conditions. Only in ripened-cheeses, proteolysis significantly increased at dose of enzymes does.

show abstract

“…In the design of the meals the following considerations were taken into account for the feasibility and to avoid country-related potential bias: meals had to fit all the nutritional habits according to previous results of our group [ 19 ], international brands had to be used in order to achieve the same nutritional composition and easy cooking techniques were to be used, so that the assumption that the TOD was maintained in the foods used in all the countries could be made. To calculate the nutrient profile of the test meals, the nutritional composition databases of EuroFIR and Nubel were upgraded including the nutrient information directly from the specific test food labelling.…”

Section: Methodsmentioning

confidence: 99%

Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundA method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available.ObjectivesTo assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Secondly, to assess how individual patient characteristics influence the expected coefficient of fat absorption (CFA) and thus to identify an individual correction factor to improve TOD.MethodsA prospective interventional study in 43 paediatric patients with CF from 5 European centres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal collection was carried out between colorimetric markers in order to include all the faeces corresponding to the fixed diet. Beta regression models were applied to assess the associations of individual patient characteristics with the CFA.ResultsMedian CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres. Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical associations were found with and age, gender, phenotype or BMI. Regression model showed no improvement of the in vitro predicted theoretical optimal dose when taking individual patient characteristics into account.ConclusionStrict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal, led to median CFA levels at the clinical target of 90% with a low variability between patients. The proposed method can be considered as a first approach for an evidence-based method in PERT dosing based on food characteristics. Results have to be confirmed in free dietary settings.

show abstract

The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment

Cited by 27 publications

References 18 publications

Trends in Dietary Intake of Total Fat and Fatty Acids Among Korean Adolescents from 2007 to 2017

Trends in Dietary Intake of Total Fat and Fatty Acids Among Korean Adolescents from 2007 to 2017

In vitro study of cheese digestion: Effect of type of cheese and intestinal conditions on macronutrients digestibility

Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis

Contact Info

Product

Resources

About